Splenic FDG uptake predicts poor prognosis in patients with unresectable cholangiocarcinoma;FDG-Aufnahme der milz prognostiziert ungünstigen verlauf bei patienten mit inoperablem cholangiokarzinom

NuklearMedizin

Volumn 53, Issue 2, 2014, Pages 26-31

  Pak, K ^a   Kim, Seong Jang ^a   Kim, I J ^a   Kim, D U ^a   Kim, K ^a   Kim, H ^a   Kim, S J ^a  

^a Pusan National University School of Medicine   (South Korea)

Author keywords

Cholangiocarcinoma; PET; Spleen

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; FLUORODEOXYGLUCOSE F 18; HEMOGLOBIN; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; BILE DUCT CARCINOMA; CANCER PROGNOSIS; CANCER SURGERY; COMPARATIVE STUDY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; BILE DUCT TUMOR; DIAGNOSTIC USE; EPIDEMIOLOGY; INTRAHEPATIC BILE DUCT; METABOLISM; MIDDLE AGED; MORTALITY; POSITRON EMISSION TOMOGRAPHY; PREVALENCE; PROGNOSIS; REPRODUCIBILITY; RISK ASSESSMENT; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; SOUTH KOREA; SPLEEN; STATISTICS AND NUMERICAL DATA; SURVIVAL RATE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CHOLANGIOCARCINOMA; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PREVALENCE; PROGNOSIS; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; REPUBLIC OF KOREA; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SPLEEN; SURVIVAL RATE;

EID: 84899704131     PISSN: 00295566     EISSN: None     Source Type: Journal    
DOI: 10.3413/Nukmed-0566-13-03     Document Type: Article

References (28)

1. 18F FDG PET in patients with primary sclerosing cholangitis and cholangiocarcinoma using visual and semiquantitative analysis. Clin Nucl Med 2011; 36: 879-883.
2. Alnafisi N, Yun M, Alavi A. F-18 FDG uptake in congestive splenomegaly. Clin Nucl Med 2002; 27: 210.
3. Anderson CD, Pinson CW, Berlin J, Chari RS. Diagnosis and treatment of cholangiocarcinoma. Oncologist 2004; 9: 43-57
4. Blechacz B, Gores GJ. Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment. Hepatology 2008; 48: 308-321.
5. Cheon YK, Cho YD, Moon JH et al. Diagnostic utility of interleukin-6 (IL-6) for primary bile duct cancer and changes in serum IL-6 levels following photodynamic therapy. Am J Gastroenterol 2007; 102: 2164-2170.
6. Gerhardt T, Milz S, Schepke M et al. C-reactive protein is a prognostic indicator in patients with perihilar cholangiocarcinoma. World J Gastroenterol 2006; 12: 5495-5500.
7. Goydos JS, Brumfield AM, Frezza E et al. Marked elevation of serum interleukin-6 in patients with cholangiocarcinoma-Validation of utility as a clinical marker. Ann Surg 1998; 227: 398-404.
8. Heikkila K, Ebrahim S, Rumley A et al. Associations of circulating C-reactive protein and interleukin-6 with survival in women with and without cancer: Findings from the British Women's Heart and Health Study. Cancer Epidem Biomar 2007; 16: 1155-1159.
9. Jaiswal M, LaRusso NF, Burgart LJ, Gores GJ. Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide-dependent mechanism. Cancer Res 2000; 60: 184-190.
10. Li J, Kuehl H, Grabellus F et al. Preoperative assessment of hilar cholangiocarcinoma by dual-modality PET/CT. J Surg Oncol 2008; 98: 438-443.
11. Lin WW, Karin M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest 2007; 117: 1175-1183.
12. Liu Y. Clinical significance of diffusely increased splenic uptake on FDG-PET. Nucl Med Commun 2009; 30: 763-769.
13. Maruoka H, Koga T, Takeo M et al. Increased splenic fluorodeoxyglucose uptake in a patient with granulomatous angitis. Intern Med 2007; 46: 909-911.
14. Mihalache F, Tantau M, Diaconu B, Acalovschi M. Survival and quality of life of cholangiocarcinoma patients: a prospective study over a 4 year period. J Gastrointest Liver Dis 2010; 19: 285-290.
15. 18Ffluorodeoxyglucose positron emission tomography in the diagnosis, staging, and follow-up of cholangiocarcinoma. Surg Oncol 2011; 20: e10-e17.
16. Nam HY, Kim SJ, Kim IJ et al. The clinical implication and prediction of diffuse splenic FDG uptake during cancer surveillance. Clin Nucl Med 2010; 35: 759-763.
17. 18F-fluorodeoxyglucose uptake during positron emission tomography/computed tomography. Nucl Med Commun 2013; 34: 64-70.
18. Patel T, Singh P. Cholangiocarcinoma: emerging approaches to a challenging cancer. Curr Opin Gastroenterol 2007; 23: 317-323.
19. Patel T. Worldwide trends in mortality from biliary tract malignancies. BMC cancer 2002; 2: 10.
20. Ruys AT, Bennink RJ, van Westreenen HL et al. FDG-positron emission tomography/computed tomography and standardized uptake value in the primary diagnosis and staging of hilar cholangio-carcinoma. HPB 2011; 13: 256-262.
21. Ruys AT, van Haelst S, Busch OR et al. Long-term survival in hilar cholangiocarcinoma also possible in unresectable patients. World J Surg 2012; 36: 2179-2186.
22. Seo S, Hatano E, Higashi T et al. Fluorine-18 fluoro deoxyglucose positron emission tomography predicts lymph node metastasis, P-glycoprotein expression, and recurrence after resection in mass-forming intrahepatic cholangiocarcinoma. Surgery 2008; 143: 769-777.
23. Sheehy N, Israel DA. Acute varicella infection mimics recurrent Hodgkin's disease on F-18 FDG PET/CT. Clin Nucl Med 2007; 32: 820-821.
24. Tabibzadeh SS, Poubouridis D, May LT, Sehgal PB. Interleukin-6 immunoreactivity in human tumors. Am J Pathol 1989; 135: 427-433.
25. Warburg O. On the origin of cancer cells. Science 1956; 123: 309-314.
26. Wluka A, Olszewski WL. Innate and adaptive processes in the spleen. Ann Transplant 2006; 11: 22-29.
27. Zasadny KR, Wahl RL. Standardized uptake values of normal tissues at PET with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose: variations with body weight and a method for correction. Radiology 1993; 189: 847-850.
28. Zhuang HM, Alavi A. 18-fluorodeoxyglucose positron emission tomographic imaging in the detection and monitoring of infection and inflammation. Semin Nucl Med 2002; 32: 47-59.